{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:18:50Z","timestamp":1789499930400,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Antiretroviral therapy has marked a transformative advancement in the management of people living with human immunodeficiency virus type-1 (HIV-1) (PLWH), converting this disease into a manageable condition. Triple-drug regimens have long been considered the gold standard for treatment. However, recent developments have focused on 2-drug regimens to mitigate the toxicities associated with polypharmacy while maintaining viral suppression and improving patient outcomes. Although the efficacy of treatment simplification is established, the impact on adverse events (AEs) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To evaluate the relative risk (RR) of developing drug-related AEs (DRAEs), DRAEs leading to treatment discontinuation (DRAEs-LD), and serious AEs, a systematic review and meta-analysis of available phase 3 and 4 clinical trials lasting at least 48 weeks and assessing treatment simplification to oral INSTIs in virologically suppressed PLWH were conducted. The study also evaluated the effects of early (ES) and late (LS) treatment regimen switches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Participants who switched to 2DR exhibited a significantly increased RR of developing DRAEs (RR\u2005=\u20056.92; confidence interval [CI]: 3.02\u201315.86,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001) and DRAES leading to discontinuation (DRAEs-LD) (RR\u2005=\u20054.41; 95% CI: 1.77\u201310.99;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001) compared to those who remained on 3DR\/4DR, with no differences observed in the RR of developing serious AEs (RR\u2005=\u20051.06; 95% CI: 0.73\u20131.55;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.76).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings indicate that there is still limited evidence to confirm that treatment simplification to oral INSTIs improves safety and tolerability profiles in the short-mid term. Our analyses emphasize the importance of evaluating symptom burden when considering therapy regimen switches in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000045152","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:03:12Z","timestamp":1762210992000},"page":"e45152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Is less truly more? \u2013 reassessing antiretroviral efficacy \u2013 a safety analysis for HIV patients switching from triple to double regimens with integrase inhibitors: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1939-4295","authenticated-orcid":false,"given":"Francisco","family":"Jover","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednico Universitario de San Juan, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez-Sanz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Antela","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Cl\u00ednico Universitario de Santiago, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"L\u00f3pez-Cavanillas","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Gilead Sciences, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Viguera-Moreno","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Gilead Sciences, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Outcomes\u201910 a Product Life-Group Company, Castell\u00f3n de la Plana, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"10","key":"R1-20260915","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/jac\/dkab168","article-title":"Redefining therapeutic success in HIV patients: an expert view.","volume":"76","author":"Antela","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S1473-3099(16)30402-9","article-title":"New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective.","volume":"16","author":"Allegranzi","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/hiv.13050","article-title":"Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.","volume":"22","author":"Punekar","year":"2021","journal-title":"HIV Med"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2352-3018(16)30015-7","article-title":"Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.","volume":"3","author":"Achhra","year":"2016","journal-title":"Lancet HIV"},{"key":"R8-20260915","first-page":"93A","article-title":"Treatment and prevention of HIV infection: recommendations from the International Antiviral Society-USA panel.","volume":"109","author":"Arnold","year":"2024","journal-title":"Am Fam Physician"},{"key":"R9-20260915","first-page":"446.e1","article-title":"Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualizaci\u00f3n enero 2022).","volume":"32","author":"Sobre el Sida","year":"2022","journal-title":"Enferm Infecc Microbiol Cl\u00edn"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials.","volume":"83","author":"Cahn","year":"2020","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial.","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial.","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-Week results from the SWORD-1 and SWORD-2 randomized clinical trials.","volume":"85","author":"van Wyk","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(21)00100-4","article-title":"Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.","volume":"8","author":"Rojas","year":"2021","journal-title":"Lancet HIV"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/QAI.0000000000002655","article-title":"Brief report: improvement in metabolic health parameters at week 48 after switching from a tenofovir alafenamide-based 3- or 4-drug regimen to the 2-drug regimen of dolutegravir\/lamivudine: the TANGO study.","volume":"87","author":"van Wyk","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"ofae560","DOI":"10.1093\/ofid\/ofae560","article-title":"Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study.","volume":"11","author":"Rolle","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12981-024-00668-7","article-title":"Virologically suppressed switch to Dolutegravir\/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States.","volume":"21","author":"Pierone","year":"2024","journal-title":"AIDS Res Ther"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s40121-022-00630-y","article-title":"Shorter time to discontinuation due to treatment failure in people living with hiv switched to dolutegravir plus either rilpivirine or lamivudine compared with integrase inhibitor-based triple therapy in a large Spanish Cohort.","volume":"11","author":"Teira","year":"2022","journal-title":"Infect Dis Ther"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"848630","DOI":"10.3389\/fimmu.2022.848630","article-title":"Long-term changes of inflammatory biomarkers in individuals on suppressive three-drug or two-drug antiretroviral regimens.","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/jac\/dkae083","article-title":"Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.","volume":"79","author":"de Lazzari","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"1279390","DOI":"10.3389\/fimmu.2023.1279390","article-title":"Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG\/3TC vs. B\/F\/TAF: the DEBATE trial.","volume":"14","author":"Cossarizza","year":"2023","journal-title":"Front Immunol"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3947\/ic.2024.0066","article-title":"Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: a systematic review and meta-analysis.","volume":"56","author":"Russo","year":"2024","journal-title":"Infect Chemother"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.3390\/jcm12247759","article-title":"Dolutegravir\/lamivudine versus tenofovir alafenamide\/emtricitabine\/bictegravir as a switch strategy in a real-life cohort of virogically suppressed people living with HIV.","volume":"12","author":"De Socio","year":"2023","journal-title":"J Clin Med"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/jac\/dkab429","article-title":"Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.","volume":"77","author":"Borghetti","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R35-20260915","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort.","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"key":"R36-20260915","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/cid\/ciae490","article-title":"Results from systematic review and meta-analysis of the efficacy and safety of two-drug versus three-drug (tenofovir\/lamivudine\/dolutegravir; TLD) regimens for HIV treatment.","volume":"80","author":"Fairhead","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R38-20260915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hiv.13526","article-title":"Sleep deficiency among people living with human immunodeficiency virus: a growing challenge.","volume":"25","author":"Reisert","year":"2024","journal-title":"HIV Med"},{"key":"R39-20260915","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1086\/498027","article-title":"Bacterial diarrhea in persons with HIV infection, United States, 1992-2002.","volume":"41","author":"Sanchez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R40-20260915","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1526-4610.2011.02025.x","article-title":"Headache among patients with HIV disease: prevalence, characteristics, and associations.","volume":"52","author":"Kirkland","year":"2012","journal-title":"Headache"},{"key":"R41-20260915","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/15402002.2020.1803871","article-title":"Insomnia, health, and health-related quality of life in an urban clinic sample of people living with HIV\/AIDS.","volume":"19","author":"Rogers","year":"2021","journal-title":"Behav Sleep Med"},{"key":"R42-20260915","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jpainsymman.2022.02.337","article-title":"HIV symptom clusters are similar using the dimensions of symptom occurrence and distress.","volume":"63","author":"Wilson","year":"2022","journal-title":"J Pain Symptom Manage"},{"key":"R43-20260915","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","article-title":"Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine.","volume":"11","author":"Wohl","year":"2018","journal-title":"Patient"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:01:41Z","timestamp":1789498901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":36,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045152","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-06-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}